AgriLabs® has introduced a new innovative custom vaccine option for swine veterinarians and producers. It combines the benefits of herd-specific autogenous vaccines with proprietary production processes and ENABL® adjuvant technology designed to improve vaccine performance.
“The custom vaccine market has seen little innovation in recent years despite a growing number of companies,” says Sean O’Hare, executive vice president of AgriLabs. “Our technological advancements allow us to deliver a custom vaccine option that is truly different from – and better designed to evolve with your health management practices than – others in the market.”
O’Hare says proprietary production processes will help AgriLabs produce custom vaccines from particular strains of certain swine diseases, such as PRRS, that have evolved to become harder for other custom vaccine manufacturers to grow. “Making custom vaccines for hard-to-grow virus strains has become a particular challenge in the industry, and our scientists have developed novel techniques to address that challenge,” O’Hare says.
In addition, O’Hare says the company’s recently patented ENABL adjuvant technology will be a key differentiator.
“ENABL novel adjuvants feature a patented lipid/polymer matrix to which antigens attach for efficient delivery to target cells,” says O’Hare. “That means higher absorption of antigen to immune cells. The result is a greater immune response – and a custom vaccine offering unlike any other.”